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IL-12p35 induces expansion of IL-10 and IL-35-
expressing regulatory B cells and ameliorates
autoimmune disease
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Paul T. Wingﬁeld5, Rachel R. Caspi4 & Charles E. Egwuagu1
Interleukin 35 (IL-35) is a heterodimeric cytokine composed of IL-12p35 and Ebi3 subunits.
IL-35 suppresses autoimmune diseases while preventing host defense to infection and pro-
moting tumor growth and metastasis by converting resting B and T cells into IL-10-producing
and IL-35-producing regulatory B (Breg) and T (Treg) cells. Despite sharing the
IL-12p35 subunit, IL-12 (IL-12p35/IL-12p40) promotes inﬂammatory responses whereas IL-35
(IL-12p35/Ebi3) induces regulatory responses, suggesting that IL-12p35 may have unknown
intrinsic immune-regulatory functions regulated by its heterodimeric partner. Here we show
that the IL-12p35 subunit has immunoregulatory functions hitherto attributed to IL-35.
IL-12p35 suppresses lymphocyte proliferation, induces expansion of IL-10-expressing and
IL-35-expressing B cells and ameliorates autoimmune uveitis in mice by antagonizing
pathogenic Th17 responses. Recapitulation of essential immunosuppressive activities of IL-35
indicates that IL-12p35 may be utilized for in vivo expansion of Breg cells and autologous Breg
cell immunotherapy. Furthermore, our uveitis data suggest that intrinsic immunoregulatory
activities of other single chain IL-12 subunits might be exploited to treat other autoimmune
diseases.
DOI: 10.1038/s41467-017-00838-4 OPEN
1Molecular Immunology Section, Laboratory of Immunology, National Eye Institute (NEI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
2 State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou 510060, China. 3 Laboratory of Immunology,
Beijing Institute of Basic Medical Sciences, Beijing 100850, China. 4 Immunoregulation Section, Laboratory of Immunology, NEI, NIH, Bethesda, MD 20892,
USA. 5 Protein Expression Laboratory, National Institute Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda,
MD 20814, USA. Ivy M. Dambuza, Chang He and Jin Kyeong Choi contributed equally to this work. Correspondence and requests for materials should be
addressed to C.E.E. (email: egwuaguc@nei.nih.gov)
NATURE COMMUNICATIONS |8:  719 |DOI: 10.1038/s41467-017-00838-4 |www.nature.com/naturecommunications 1
The interleukin 12 (IL-12) family of cytokines (IL-12, IL-23,IL-27, and IL-35)1–4 is known to consist of 4 members andeach member is composed of two subunits, an α-subunit
(IL-12p35, IL-23p19, and IL-27p28) and a β-subunit (IL-12p40,
Ebi3)1. The subunits are each encoded by separate chromosomes
and their expression is regulated independently5. The effects of
IL-12 cytokines on host immunity derive from the fact that each
of the α and β subunits is the target of microbial Toll-like receptor
(TLR) agonists that activate innate immune cells, including
monocytes and antigen-presenting dendritic cells5. Depending on
the pathogen, activation of TLRs on the dendritic cells induces
the transcription of distinct repertoires of the IL-12 α and β
subunit genes6–9. The predominant IL-12 cytokine(s) produced
within the immediate environment of differentiating naive lym-
phocytes is thought to inﬂuence the developmental decisions of
the lymphocytes and thereby determines the lymphocyte subsets
that would dominate the ensuing immune response. IL-12 family
cytokines are therefore considered to have critical functions in
regulating the initiation, intensity, duration, and quality of
adaptive immunity1, 10, 11.
It is notable that the three α subunits are structurally related
and each conceivably can pair with either of the structurally
homologous β subunits1, 10. Pairing of the α-subunits, IL-12p35
or IL-23p19 with IL-12p40, gives rise to the two pro-
inﬂammatory members IL-12 and IL-23, respectively, whereas
the two immunosuppressive members of the family, IL-27 and
IL-35, derive from pairing of IL-27p28 or IL-12p35 with Ebi31, 11.
In a previous study, we showed that IL-12p40-deﬁcient mice are
resistant to experimental autoimmune uveitis (EAU), suggesting
that endogenous or IL-12 or IL-23 is required for induction and
progression of EAU12. On the other hand, inﬂammatory stimuli
induce microglial cells of the neuroretina to produce IL-27, and
this immune-suppressive IL-12 member has been shown to
inhibit Th17-mediated ocular inﬂammation and contribute to the
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Fig. 1 p35 monomer and homo-dimer suppressed T and B cell proliferation. Secreted rIL-12p35 was partially puriﬁed by His-tagged afﬁnity chromatography
using Ni-NTA followed by two consecutive cycles of gel ﬁltration using Supercryl S-200 (HR Hiprep 16/60) and Superose-6 (HR 10/30) FPLC columns. a
rIL-12p35 in insect cell supernatant was sequentially puriﬁed by Ni-NTA Puriﬁcation system, size-exclusion Centricon ﬁltration and Supercryl S-200
chromatography. Protein from Ni-chelate afﬁnity column was applied to a Sephacryl S-200 column and the elution prolife screened by SDS-PAGE under
non-reducing conditions is shown. Analysis of the FPLC column fractions by non-denaturing SDS-PAGE indicates presence of p35−p35 homo-dimer and p35
monomer in the rIL-12p35 preparation. b Fractions 20–21 (p35−p35) and 29–30 (p35) were fractionated under non-reducing condition on SDS-PAGE and
analyzed by the western blotting. c Further puriﬁcation on Superose-6 FPLC column. Analysis of the main peak by non-reducing or reducing SDS-PAGE; Data
from Coomassie Blue stained gel and western blot analysis are indicated. Samples 1 and 2 are duplicates. d, e The peak protein fraction from Superose-6
column was further puriﬁed by size-exclusion Centricon ﬁltration and subjected to sedimentation equilibrium analyses under non-reducing d or reducing e
condition. The p35 is clearly dimeric in the absence of reductant and monomeric when reduced. f Naive CD4+ T cells were stimulated with anti-CD3/CD28
in medium containing p35 or p35−p35 and after 72 h the effect of p35 or p35−p35 on proliferation was assessed by [3H]-thymidine incorporation assay. g
Puriﬁed CD19+ B cells were stimulated with LPS for 2 days in medium containing p35−p35 or p35 and analyzed by [3H]-thymidine incorporation assay. h
Puriﬁed CD19+ B cells were stimulated with LPS for 2 day in medium containing p35 or rIL-35 and analyzed by western blotting. i, j CD4+ T cells were
stimulated with anti-CD3/CD28 for 3 days. The cells were then cultured in serum-free medium for 2 h, followed by stimulation with IL-6 or IL-12 for 10, 30,
and/or 60min in the presence or absence of p35. Whole cell lysates were analyzed by western blotting using indicated Abs. Results represent at least three
independent experiments and were analyzed using Student’s t-test (two-tailed). Data are mean± SEM. (***P< 0.001; ****P<0.0001)
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maintenance of ocular immune privilege13–15. These and other
reports underscore the emerging consensus that IL-12 and IL-23
are potential therapeutic targets that can be used to treat
inﬂammatory diseases, whereas IL-27 and IL-35 are potential
biologic agents for suppressing autoimmune diseases such as
uveitis and multiple sclerosis. Aside from functioning as hetero-
dimers, the individual subunits can also function autonomously
as monomers or homo-dimers. For example, the IL-12p35 sub-
unit has been shown to act as negative regulator of IL-27
responses in an experimental model of arthritis16. IL-27p28 also
antagonizes IL-27 signaling, functioning as a natural antagonist of
gp130-mediated signaling that can be exploited therapeutically to
mitigate inﬂammatory diseases mediated by cytokines that utilize
gp13017. On the other hand, IL-12p40 is secreted independently
of IL-12 in serum of patients with pulmonary sarcoidosis and
considered a useful clinical marker for disease activity in pul-
monary sarcoidosis18. Similarly, IL-12p40 and disulﬁde-linked
p40−p40 homo-dimer are secreted in serum of patients with
multiple sclerosis and are associated with suppressing neurolo-
gical dysfunctions or endotoxemia by antagonizing IL-12 sig-
naling and Th1 expansion19, 20. Of relevance to the development
of novel therapeutic cytokines/biologic agents is the proposition
that altering the balance between the different IL-12 subunits may
be a strategy to regulate inﬂammatory responses.
IL-35 is the other anti-inﬂammatory member of the IL-12
family of cytokines21–23. IL-35 is composed of Ebi3, a β-chain
subunit encoded by the Epstein−Barr virus (EBV)-induced gene 3
(Ebi3, also known as IL27b), and the IL-12p35 α subunit encoded
by IL12a21, 22, 24. Initial reports indicated that IL-35, produced
mainly by T cell contributes to the suppressive activities of reg-
ulatory T (Treg) cells21. However, subsequent reports have shown
that IL-35 is also a physiological inducer of IL-10-producing
regulatory B (Breg) cells, as well as, a relatively rare B cell sub-
population that produces IL-3525. In addition, IL-35 confers
protection of mice from uveitis or encephalitis by inhibiting Th17
and Th1 auto-reactive pathogenic T cells while promoting the
expansion of B and T cells25, 26. Despite interest in IL-35 as
potential biologic agent for treatment of autoimmune diseases,
the mechanism by which it mediates its biological effects is not
fully understood. Although it is implicitly assumed that immu-
nosuppressive activities of IL-35 derive from pairing of IL-12p35
and Ebi3, it is unknown whether the single chain proteins,
IL-12p35 and Ebi3, possess intrinsic biological activities. More-
over, the relative contribution of either chain to the immune-
regulatory functions of IL-35 is unclear. In this study, we have
produced mouse recombinant IL-12p35 (rIL-12p35) and rEbi3
and examined whether either protein can recapitulate some of the
inhibitory activities of IL-35. Our data indicate that IL-12p35,
while not readily detectable in vivo in the steady-state, possesses
at least some of the immune-regulatory properties of the
heterodimeric IL-35 cytokine and when used therapeutically it is
able to control autoimmune disease affecting the neuroretina.
Results
IL-12p35 suppresses proliferation of T and B cells. Biologically
active, heterodimeric IL-35 (rIL-35) was previously produced by
expressing the IL-12p35 and Ebi3 cDNA constructs in insect cells
using the pMIB bicistronic vector25. In this study, we used the
pMIB expression system to produce the mouse recombinant IL-
12p35 (rIL-12p35) or Ebi3 (rEbi3) single chain protein; the
powerful polyhedrosis Baculovirus early promoter drove expres-
sion of the cDNA construct and secretion was directed by the
honeybee melittin (HBM) signal peptide (Fig. 1 and Supple-
mentary Fig. 1). The secreted rIL-12p35 migrates on
non-denaturing (non-reduced) SDS-PAGE as a p35−p35 homo-
dimer of ~ 57 kDa and a p35 monomer of ~ 27 kDa (Fig. 1a).
Analyses of FPLC fractions 20–21 and 29–30 by western blotting
conﬁrmed that the secreted p35−p35 homo-dimer and the p35
monomer are indeed IL-12p35 (Fig. 1b). The partially puriﬁed
proteins were subjected to additional puriﬁcation on superpose-6
FPLC columns and by enrichment with Ultra centrifugal
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Fig. 2 p35 induced an IL-35-producing Breg cells in vivo. aWe injected C57BL/6 mice with LPS (15 µg/mouse) and after 4 days we isolated CD19+ B cells from
the spleen (purity> 96%), lysed the cells and subjected the whole cell lysates to western blot analysis. b Intraocular inﬂammation (uveitis) was induced in
C57BL/6J mice by immunization with the ocular autoantigen, IRBP in CFA as described in Methods section. Mice were killed 21 days post-immunization and cell
lysate of the spleen was analyzed by western blotting (non-reduced condition). Results represent two independent experiments
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size-exclusion ﬁlters (Centricon). The puriﬁed p35 monomer and
homo-dimeric (p35−p35) proteins used in all studies described
here were veriﬁed to be IL-12p35 by western blot analysis using
IL-12p35-speciﬁc antibodies, under reducing or non-reducing
condition (Fig. 1c). The puriﬁed proteins (fractions 20–21 and
29–30) were also analyzed under native conditions by sedi-
mentation equilibrium to directly determine their molecular
weights. The results conﬁrmed that rIL-12p35 can exist in solu-
tion as a homo-dimer (p35−p35) with a molecular weight of ~ 56
kDa (Fig. 1d) and predominantly as a monomer of ~ 27 kDa
under reduced condition (Fig. 1e). While the rIL-12p35
preparation contained p35 and p35−p35 proteins, we cannot
rule out possibility that presence of both moieties might be
inﬂuenced by the oxidative state under in vivo conditions or
during puriﬁcation of the secreted proteins. Assuming that afﬁ-
nity of hetero-dimerization might be stronger than homo-
dimerization, it is conceivable that p35 does not accumulate in
concentrations required for homo-dimerization in vivo, but
would be mopped up forming heterodimers with Ebi3 (e.g., IL-
35) or p40 (IL-12). Nonetheless, our in vitro studies show that
either p35 or p35−p35 is able to suppress T cell (Fig. 1f) and B cell
(Fig. 1g) proliferation in dose-dependent manner, establishing
that the monomer and homodimer are both biologically active.
IL-35 was previously shown to inhibit lymphocyte proliferation
by upregulating p27kip1 and thereby restricting progression
through the S phase of the cell cycle27, 28. We therefore activated
CD19+ cells with LPS in medium containing p35 or rIL-35.
Interestingly, while cyclin E and D1 levels are comparable in all
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Fig. 3 p35 and p35−p35 mitigated experimental autoimmune uveitis (EAU). EAU was induced in C57BL/6J mice and some mice were treated with p35
−p35 or p35. Fundus images a, b and histology sections c of the retina at day 14 or day 21 after EAU induction. Fundus images were taken using an
otoendoscopic imaging system. Note inﬂammation with blurred optic disc margins and enlarged juxtapapillary area (black arrows), retinal vasculitis with
moderate cufﬁng (blue arrows), and yellow−whitish retinal and choroidal inﬁltrates (white arrows). Clinical scores and assessments of disease severity were
based on pathological changes at the optic disc and retinal and choroidal tissues. H&E histological sections c show inﬂammatory cells in retina and vitreous
(blue arrows) and numerous retinal folds, a hallmark of severe retinitis yellow highlight. OPN, optic nerve; GCL, ganglion cell layer; INL, inner nuclear layer;
ONL, outer nuclear layer; RPE (retinal pigmented epithelial cell layer) and choroid. d Layered structure of the retina was visualized by SD-OCT.
Representative OCT images taken on day 18 after disease induction show markedly increased inﬂammatory cells (white arrows) in the vitreous, retina and
posterior chamber of the untreated mice compared to those treated with p35 or p35−p35. Retinal layer destructions (red arrow). e ERG analysis of the
retina on day 20 after EAU induction. The averages of light-adapted or dark-adapted ERG b-wave amplitudes are plotted as a function of ﬂash luminance
and values are mean± SEM from four animals in each group. Results represent at least three independent experiments and were analyzed using Student’s
t-test (two-tailed). (*P< 0.05; **P< 0.01; ***P< 0.001; ****P< 0.0001)
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samples, p35-treated B cells displayed higher level of p27Kip1
compared to untreated cells (Fig. 1h), suggesting that IL-12p35
might inhibit B-lymphocyte proliferation by inducing cell-cycle
arrest. Western blot analysis of TCR-activated CD4+ T cells
revealed that p35 could not activate STAT1, STAT3, or STAT4
but provided suggestive evidence that p35 might suppress lym-
phocyte proliferation by inhibiting IL-6-induced STAT3 activa-
tion (Fig. 1i) or IL-12-induced activation of STAT4 (Fig. 1j).
Taken together, these results suggest that IL-12p35 possesses
intrinsic anti-proliferative activities.
It was however of interest to examine whether monomers and
homo-dimers of IL-12p35 and/or Ebi3 can be detected in vivo
during inﬂammatory immune responses of mice to infection, as
may occur during sepsis. We therefore injected C57BL/6 mice with
LPS. After 4 days, we isolated CD19+ B cells from the spleen, lysed
the cells and subjected the whole cell lysates to western blot analysis.
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***P< 0.001; ****P< 0.0001)
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To our surprise, we detected not only the monomeric proteins but
also, to a lesser amount, the p35−p35 and Ebi3−Ebi3 homodimers
in the spleen cells of mice treated with LPS (Fig. 2a), suggesting that
formation of p35−p35 homodimer may occur under conditions of
intense inﬂammation. To conﬁrm this ﬁnding, we next examined
whether the p35−p35 homodimer also exists in vivo during
experimental uveitis, an inﬂammatory disease of the eye. Analysis of
whole cell lysate of the spleen by western blotting (under
non-reduced condition) revealed signiﬁcant expression of the p35
monomer in EAU mice treated with p35 compared to control mice
(Fig. 2b). In contrast, we could not detect the p35−p35 homodimer
(Fig. 2b), suggesting that signiﬁcant amounts of the homodimer
may not be produced in the periphery to allow its detection in the
spleen during this localized inﬂammation of the immune privileged
neuro-retinal tissue. It is also of note that Ebi3 is constitutively
expressed with very little IL-12p35. The western blot analysis
showing signiﬁcant upregulation of p35 (Fig. 2b; left-most panel)
thus provide suggestive evidence that the induced p35 couples with
constitutively produced Ebi3 to produce IL-35 in p35-treated mice
during intraocular inﬂammation.
IL-12p35 suppresses autoimmune uveitis. The function of
IL-12p35 in vivo is complicated by the shared usage of IL-12p35
by IL-12 and IL-35. Moreover, the role of IL-12p35 in auto-
immune disease remains unresolved and controversial as
IL-12p35-deﬁcient mice are protected against collagen-induced
arthritis29 while they develop exacerbated experimental auto-
immune encephalitis (EAE)30. EAU shares essential immuno-
pathogenic features with EAE and serves as an animal model of
human uveitis. To directly examine the immunoregulatory func-
tions of IL-12p35 during an organ-speciﬁc autoimmune disease,
we induced EAU in C57BL/6J mice by active immunization with
the ocular autoantigen, IRBP (interphotoreceptor retinoid-binding
protein), and administered p35 or p35−p35 to some of the mice
concurrently with immunization. Disease progression and severity
were monitored by funduscopy, histology, optical coherence
tomography (OCT) and electroretinogram (ERG). Consistent with
published reports31–33 funduscopic images taken 14 or 21 days
after EAU induction showed that the untreated mice developed
EAU characterized by optic disc inﬂammation (black arrow),
vasculitis with cufﬁng (blue arrow), sclerotic blood vessels (white
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arrow), and choroidal and retinal deposits (Fig. 3a, b). Histological
analysis of the eyes 21 days after EAU induction further shows
that the untreated mice developed several retinal folds (yellow
asterisks) and increased numbers of inﬂammatory cells in the
retina/vitreous (blue arrows). Evidence of these hallmark features
of uveitis was not observed in mice treated with p35−p35 or p35
(Fig. 3c). The protective effects of p35 or p35−p35 was further
conﬁrmed by OCT analysis showing substantial presence of
inﬂammatory cells in the optic nerve head and development of
papillitis in untreated but not p35 or p35−p35-treated mice
(Fig. 3d). Changes in ERG are indicative of alterations in neural
activity and visual functions of photoreceptor and second-order
neurons during ocular inﬂammation34. Photopic (light adapted)
ERG responses on day 21 post-immunization were characterized
by signiﬁcantly lower b-wave amplitudes in eyes of untreated mice
(Fig. 3e), suggesting that p35−p35 treatment might preserve cone
signaling functions. Similar to the light-adapted responses,
untreated mice elicited scotopic (dark adapted) ERG responses of
signiﬁcantly lower b-wave amplitudes, conﬁrming the neuropro-
tective effect of IL-12p35 during EAU. It is important to note that
we observed no substantial difference between p35 and p35−35 in
these studies, suggesting that they can be used interchangeably.
IL-12p35 inhibits Th17 and induces Treg cells during uveitis.
Th17 and IL-17/IFN-γ-expressing (DP-Th17) T cells increase in the
spleen, draining lymph nodes (LN) and retina of mice with EAU
and have been implicated in human and mouse uveitis13, 25, 35. It is
of note that expansion of DP-Th17 cells is also associated with
EAE36 and Crohn’s disease37 and considered as a hallmark of
uveitis35. We therefore isolated cells from the spleen, draining LN
and retina of the mice 21 days after induction of EAU and exam-
ined whether p35 reduced EAU severity by inhibiting the expansion
of these pathogenic T-helper subsets. In line with our prediction,
frequency of Th17 and to a lesser extent DP-Th17 cells was reduced
in the spleen and draining LN of p35-treated mice compared to
untreated mice (Fig. 4a). Reduction in the frequency of Th17-DP or
Th17 cells in the treated mice suggests that p35 inhibited uveitis, in
part, by targeting these pathogenic T-helper subsets. We further
show that the decrease in Th17 cells was accompanied by increase
of IL-10-expressing Foxp3+ and Tr1 regulatory T cells in the LN
(Fig. 4b). Given the centrality of IL-10 in the suppression of
inﬂammatory responses in several human and experimental auto-
immune diseases, we validated the FACS data showing expansion of
IL-10-producing regulatory T cells by RT-PCR (Fig. 4c) and ELISA
(Fig. 4d). Interestingly, CD4+ T cells from p35-treated mice did not
proliferate efﬁciently in response to IRBP or Con A (Fig. 4e),
indicating that p35 might induce a hypo-proliferative state in vivo.
Microglia and other myeloid cells also contribute to EAE pathology
by enhancing Th17 effector functions38. We therefore examined
whether p35 treatment inhibited the recruitment of lymphoid and
myeloid cell types into the retina during EAU. We observed sig-
niﬁcant reductions in percentages of Th1, Th17 (Fig. 4f) or myeloid
(Fig. 4g) cells in the retinae of the p35-treated mice (21 days after
EAU induction). This correlated with reduced expression of CXCR3
and α4 integrin (Fig. 4h), suggesting that p35 might also mitigate
uveitis by suppressing trafﬁcking of inﬂammatory cells into the
retina during EAU.
IL-12p35 induces expansion of Bregs. IL-35 suppresses
inﬂammation by inhibiting Th17 cells while inducing expansion
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of IL-10 and/or IL-35-expressing T and B cells21, 25, 39. To
investigate the relative contribution of IL-12p35 or Ebi3 to
immune-suppressive functions of IL-35, we activated naïve
CD4+ T cells with anti-CD3 and anti-CD28 antibodies in med-
ium containing p35, rEbi3 and/or rIL-35. While rEbi3 or p35
inhibited proliferation of the primary CD4+ T cells, the growth
inhibitory effect induced by either subunit alone was less com-
pared to rIL-35 (Fig. 5a). While consistent with the data pre-
sented in Fig. 1f, it is interesting to note that effects of p35 and
Ebi3 on T cell proliferation in Fig. 5a is less dramatic. This dif-
ference can be attributed to inherent variability of thymidine
incorporation assays, especially when performed at different
times and with different batches of Thymidine. In a previous
report, we showed that IL-35 induces the expression of IL-10 and
IL-35, as well as the expansion of IL-10- and IL-35-expressing B
cells25. We therefore examined whether co-expression of
IL-12p35 and Ebi3 is required for transcriptional activation of
genes that code for IL-10 and/or IL-35. We activated CD19+ B
cells with LPS in medium containing p35 or rEbi3 and whereas
p35 induced signiﬁcant upregulation of IL-10, p35 and Ebi3
mRNAs, rEbi3 had modest or no effect on transcription of these
genes (Fig. 5b). Taken together, these observations suggest that
the inhibition of lymphocyte proliferation by IL-35 may derive
from synergistic inhibitory effects of IL-12p35 and Ebi3, while
transcriptional activation of Il10, Il12a, and Ebi3 mainly requires
IL-12p35. Thus, each IL-35 subunit may exert distinct and
overlapping effects on lymphocytes that can be exploited ther-
apeutically. Recent reports have also shown that IL-35 induces the
expansion of IL-10-expressing and IL-35-expressing CD138+ B
cells26, 40. To examine effects of p35 on CD138+ B cells, we
activated CD19+ B cells with LPS and cultured the cells in
medium with or without p35. FACS and intracellular cytokine-
staining analyses show that p35 induced expansion of IL-10-
producing B cells characterized by the CD38hiBcl6hiBlimp-1hi
phenotype (Fig. 5c–f), suggesting that in addition to activation of
anti-inﬂammatory genes, IL-12p35 can also induce the expansion
of Breg cells and possibly promote the development of B cells
toward plasma cell differentiation.
Breg cells are induced in vivo by p35 treatment. We have shown
that p35 induces B cells in vitro and also inhibits autoimmune
inﬂammation induced by active immunization of mice with IRBP.
We next examined whether B cells induced in the spleen of EAU
mice by p35 can be used to suppress uveitis. EAU was induced in
C57BL/6J mice by active immunization with IRBP and some of
the mice were treated with PBS or p35. Draining LN and spleen
cells were isolated on day 21 post-immunization and re-
stimulated ex vivo with IRBP in medium containing PBS or
p35. FACS and intracellular cytokine-staining analyses of CD19
+-gated cells or CD4+-gated cells indicate marked increase of IL-
35-expressing CD19+ cells in mice treated with p35 compared to
PBS, reﬂecting enhanced expansion of IL-35-producing B cells in
the spleen and LN of the p35-treated mice (Fig. 6a). Next, we
adoptively transferred 10 million of the ex vivo re-stimulated cells
from the spleen and LN of the EAU mice into naive syngeneic
mice and assessed the development of EAU 10 days later.
Whereas mice that received uveitogenic cells from the PBS-
treated mice developed full-blown EAU 10 days after the adoptive
transfer of the IRBP-speciﬁc pathogenic T cells, mice that
received uveitogenic cells from the p35-treated mice had mild
disease as indicated by funduscopy (Fig. 6b). This result suggests
that in vivo exposure of the EAU-inducing uveitogenic T cells to
p35, attenuated their capacity to transfer uveitis. Consistent with
EAU induced by active immunization with IRBP, the percentage
of Th1 and Th17 cells was decreased in the retinae of mice that
received p35-treated uveitogenic cells and coincided with increase
of IL-10-producing CD4+ T cells (Fig. 6c). Similar analysis of cells
from the retinae, lymph nodes and spleen revealed signiﬁcant
increases in IL-10-producing Breg cells in the EAU mice exposed
to p35 in vivo compared to control mice treated with PBS
(Fig. 6d), providing evidence that p35 might suppress EAU, in
part, by inducing B cells in vivo.
Immune-suppressive effects of IL-12p35 require IL-12Rβ2.
IL-35 mediates its effects in lymphocytes through signaling
pathways that require the IL-12 family cytokine receptor,
IL-12Rβ21, 25, 41. Here, we have used mice that do not express
IL-12Rβ2 to investigate whether the anti-inﬂammatory activities
of p35 is mediated through the activation or suppression of sig-
nals downstream of the IL-12Rβ2 receptor. We isolated cells from
the spleen of WT or IL-12Rβ2KO mice, sorted CD19+ B cells and
activated the cells with LPS for 3 days in the presence or absence
of p35. In line with data presented above (Fig. 1h), p35 sup-
pressed the proliferation of the WT B cells whereas the loss of IL-
12Rβ2 in B cells abrogated the inhibitory effect of p35 (Fig. 7a).
We next examined whether the loss of IL-12Rβ2 would also
inhibit p35 induced expansion of regulatory B cells. Sorted CD19
+ B cells from the spleen of WT or IL-12Rβ2KO mice were
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activated with LPS for 3 days in the presence or absence of p35
and analyzed by the intracellular cytokine-staining assay. Con-
sistent with data shown in Fig. 5e, stimulation of WT B cells with
p35 induced expansion of IL-35-expressing B cells (Fig. 7b, c). In
contrast, stimulation of IL-12Rβ2 deﬁcient B cells with p35 did
not induce expansion of the IL-35-producing B cells (Fig. 7b, c).
Taken together, these observations suggest that p35 requires IL-
12Rβ2 to mediate its anti-inﬂammatory activities and that it
might do so by interfering with critical signaling pathways that
are dependent on this important IL-12 family receptor subunit.
Discussion
Our current understanding of the immunobiology of IL-35 or its
subunits (IL-12p35 and Ebi3) is still rudimentary. However,
recent reports indicate that IL-35 and IL-35-producing regulatory
B (i35-Breg) and T cells (iTR35) are critical regulators of auto-
immune diseases and cancer progression1, 10, 25, 26. In contrast to
subunits of IL-12 and IL-23, which are secreted as covalently
linked heterodimers, IL-12p35 and Ebi3 are secreted as inde-
pendent subunits and published reports indicate that the two
subunits associate during inﬂammatory conditions to form the
bioactive heterodimer1, 10, 42. In this study, we have used
recombinant IL-12p35 and Ebi3 to directly examine whether
these IL-35 subunit proteins possess intrinsic immune-
suppressive activities independent of their heterodimeric part-
ner. We found subtle differences between the biological activities
of the heterodimeric IL-35 cytokine and each of its constituent
subunit proteins. While Ebi3 and IL-12p35 inhibited lymphocyte
proliferation, Ebi3 consistently exhibited a higher inhibitory effect
compared to IL-12p35. However, the heterodimeric IL-35 cyto-
kine exhibited higher suppressive activity compared to either
subunit protein. On the other hand, IL-12p35 upregulated
expression of IL-10, p35 and Ebi3 mRNAs while Ebi3 had neg-
ligible effect on the expression of these transcripts. In addition,
IL-12p35 induced the expansion of IL-10 B and i35-B cells, albeit
to a lesser extent as the native IL-35. Thus, IL-12p35 more so than
Ebi3 appears to manifest some of the immune-regulatory func-
tions that had hitherto been attributed to IL-35.
An important unresolved issue relates to the bioavailability of
the heterodimeric IL-35 in vivo and in particular, how stability of
the heterodimer is maintained and regulated under physiological
conditions. It has been suggested that independent secretion of
IL-12p35 and Ebi3 might ensure exquisite regulation of the
duration of the immune-suppressive action of IL-35, thereby
avoiding inducing a permanent state of immune suppression that
would otherwise ensue if IL-35 were to persist as a covalently
bound IL-12p35: Ebi3 heterodimer. The IL-35 subunit proteins
are not disulﬁde-linked and Alanine/Serine-scanning mutagenesis
studies have revealed that mutations of critical residues associated
with dimerization of p35 or Ebi3 to form IL-12 and/or IL-27
could not prevent generation of p35: Ebi3 heterodimer, suggest-
ing that IL-35 has unique criteria for subunit pairing that is
distinct from other IL-12 members43. In a previous study, we
produced recombinant heterodimeric IL-35 cytokine in trans-
fected insect cells and the puriﬁed heterodimeric cytokine isolated
from the insect cells supernatants was used to effectively ame-
liorate uveitis in mice25. Interestingly, in this study we produced
recombinant IL-12p35 in insect cells and found that in addition
to the secreted IL-12p35 monomeric protein; substantial amounts
of p35-p35 homodimer was also present. We also detected both
p35 and the p35-35 homodimer in mice immunized with LPS,
suggesting that the p35−p35 homodimer may be produced in vivo
in response to acute systemic inﬂammation as may occur in
septicemia. On the other hand, while the p35 monomeric protein
was detected in the spleen of EAU mice, we could not detect the
p35−p35 homodimer, indicating that signiﬁcant amounts of the
homodimer may not be produced in the periphery to allow its
detection in the spleen during the localized inﬂammation of the
immune privileged neuro-retinal tissue. In view of the fact that
IL-12p35 and Ebi3 contain 7 and 4 cysteine as well as 10 and 3
methionine residues22, respectively, it is conceivable that these
amino acids may render p35 and Ebi3 “sticky” and might con-
tribute to propensity to form p35:p35 or Ebi3:Ebi3 homodimers.
This raises the possibility that the increase of these homodimers
during intense inﬂammation could contribute to immune-
suppression in vivo. On the other hand, increase in p35−p35
homodimer may also provide a mechanism for limiting the
bioavailability of the heterodimeric IL-35 in vivo. It is however of
note that Il12a gene transcription is stringently regulated and it’s
in vivo level is relatively low. Thus, while our data suggest that
p35 or p35−p35 homodimer can be used as Biologics to treat
inﬂammatory disease, their efﬁcacy may require high and non-
physiological levels of the protein.
Another important issue relates to the promiscuous chain
pairing/sharing exhibited by IL-12 family cytokines. Pairing of an
αsubunit protein with IL-12p40 is suggested to promote
pro-inﬂammatory responses while pairing to Ebi3 is generally
associated with immune-suppression. Validity of these assump-
tions, if proven correct, will undoubtedly have implications in
context of efforts to develop Biologics based on IL-12 family
cytokines. However, the difﬁculty of predicting the immunolo-
gical outcome of various combinations of α/βIL-12 subunit pro-
teins is underscored by the recent discovery of IL-39, a novel
pairing of Ebi3 and IL-23p19 that mediates pro-inﬂammatory
responses in Lupus-like mice44. In another study, a genetically
engineered novel IL-12-like cytokine composed of IL-12p40/IL-
27p28 was found to exhibit immunosuppressive activities and
effective in treating uveitis45, further confounding our under-
standing of how the various IL-12 α and β subunits might
inﬂuence the outcome of host immune responses. Production of
large amounts of IL-12 single chain subunit proteins in vivo also
raises the possibility that the single chain proteins may compete
for pairing, altering the pattern or repertoire of IL-12 family
cytokines secretion and thereby providing an additional
mechanism for regulating the nature, quality and/or outcome of
the immune response. The chain-sharing theme also extends to
receptor use, as several IL-12 family cytokines utilize the same
receptor chains1. In this study, we have shown that p35 alone, in
the absence of its heterodimeric partner Ebi3, antagonizes sig-
naling pathways utilized by pro-inﬂammatory cytokines like IL-6
and IL-12. We have also shown that p35 mediated inhibition of
lymphocyte proliferation and expansion of B cells required sig-
naling through the IL-12Rβ2. This is reminiscent of the antag-
onism of IL-12-driven responses by the competing of p40 homo-
dimers for binding to IL-12Rβ146, 47. These additional layers of
complexity highlight the importance of not only studying the
immune-regulatory activities of the heterodimeric cytokines but
also the intrinsic activities of the subunit proteins as we have done
in this study.
In summary, we have presented the novel ﬁndings that p35 can
suppress lymphocyte proliferation, induce expansion of B cells
and ameliorate uveitis by promoting expansion of Tregs/Bregs
while antagonizing pathogenic Th17 responses. These ﬁndings
suggest that IL-12p35 possesses immune-regulatory functions
that had hitherto been attributed to IL-35. However, these results
do not necessarily indicate that IL-35 and IL-12p35 exert identical
and redundant immune-suppressive functions in vivo. In fact,
while p35 possesses intrinsic lymphocyte growth inhibitory
effects, induced expansion of Breg cells and suppressed EAU, its
immunosuppressive effects were less compared to IL-35. More-
over, IL-35 activates STAT1, STAT3 and STAT4 signaling
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pathways25, 39, 41, while p35 antagonized IL-6 and IL-12 signaling
pathways and could not activate STAT pathways. The inhibitory
effect of p35 on lymphocyte proliferation was also less compared
to Ebi3, suggesting that the full complement of the nuanced
immune-regulatory functions of IL-35 might require both Ebi3
and IL-12p35. Thus, IL-12p35 might be promoting expansion of
Bregs while Ebi3 synergizes with p35 in suppressing lymphocyte
proliferation. Finally, the thrust of this study was to circumvent
the labor-intensive efforts required for the production of large
amounts of IL-35 for therapeutic use. Our demonstration that
IL-12p35 can recapitulate some of the immunosuppressive
activities of IL-35 is exciting and offers promise for the ther-
apeutic use of p35 for in vivo and in vitro expansion of B and
T cells. Data presented here also suggest that other single chain
IL-12 family protein subunits should be explored as a potential
new class of therapeutic cytokines.
Methods
Mice. Wild type C57BL/6j and IL-12Rβ2KO mice on C57BL/6j genetic background
were purchased from Jackson Laboratory. Mice were maintained and used in
accordance with NEI/NIH Animal Care and Use Committee (ACUC) guidelines
(ASP Protocol # EY000262-19 & EY000372-14) and the study protocol was
approved by the ACUC Committee. Both male and female mice of 6–8 weeks old
were used and the mice were randomized for all the studies described.
Production and characterization of mouse rIL-12p35 and rEbi3. Mouse
recombinant Il12a and Ebi3 cDNA constructs were generated by recombinant PCR
(Il12a forward: 5′-CGCGGATCCATTGGCCAGGGTCATTCCAGT-3′, reverse:
5′-CCGCTCGAGGGCGGA GCTCAGATAG-3′; Ebi3 forward:
5′-CGCGGATCCAGAAACAGCTCTCGTGGCTCT-3′, Ebi3 reverse:
5′-TCCCCGCGGGGGCTTATGGGGTGCACTTTCTAC-3′). The IL-12p35 or
Ebi3 cDNA was cloned into a 3.6 kb pMIB vector containing an amino-terminal
melittin (HBM) secretion signal sequence and polyhistidine tags to facilitate iso-
lation and characterization and expression of the constructs was driven by Bacu-
lovirus immediate-early promoters from the polyhedrosis virus (Catalog # V8030-
01; Invitrogen, Carlsbad, CA). The expression construct was then transfected into
insect high ﬁve cells and stable transfectants were identiﬁed by drug selection
(Blasticidin S; 100 µg/ml). To ensure that the recombinant clone expressed bona
ﬁde IL-12p35 or Ebi3, we isolated the expression vector (HBM-p35-Flag-His or
HMB-Ebi3-V5-His) and veriﬁed that no mutations were introduced during cloning
or drug selection by DNA sequencing. The recombinant protein(s) secreted by the
insect cells was sequentially puriﬁed by Ni-NTA Puriﬁcation system (Invitrogen),
size-exclusion Centricon ﬁltration and two consecutive cycles of fast performance
liquid chromatography (FPLC) on Supercryl-200 and Superose-6 columns. The
rIL-12p35 and Ebi3 proteins were further characterized by SDS-PAGE, Western
blot/immunoprecipitation and sedimentation equilibrium ultracentrifugation.
Induction of EAU. EAU was induced by active immunization with 150 µg bovine
interphotoreceptor retinoid-binding protein (IRBP) and 300 µg human IRBP
peptide, amino acid residues 1–20 (IRBP1–20) in 0.2 ml emulsion 1:1 v/v with
Complete Freund’s adjuvant (CFA) containing Mycobacterium tuberculosis strain
H37Ra (2.5 mg/ml). Mice also received Bordetella pertussis toxin (0.3 µg/mouse)
concurrent with immunization. On the day of immunization and every other day
until day 13 post-immunization, some mice were treated with either p35 or
p35−p35 (100 ng/mouse). The disease progression and severity was established and
monitored by fundoscopy, histology, optical coherence tomography (OCT) and
electroretinography (ERG) as described previously25, 34, 48. Investigator was blin-
ded to the group allocation during the EAU experiments and when assessing
disease outcome or score. Eyes for histological evaluation were harvested 21 days
post-immunization, ﬁxed in 10% buffered formalin and serially sectioned in the
vertical pupillary-optic nerve plane. All sections were stained with hematoxylin and
eosin. For adoptive transfer of EAU, EAU was induced by active immunization
with IRBP and draining LN and spleen cells isolated from mice treated with p35 or
control untreated mice were re-stimulated ex vivo with IRBP. The cells (1 × 107)
were then transferred to naive syngeneic mice I.V and 10 days later development of
EAU was examined by fundoscopy.
Imaging mouse fundus. Fundoscopic examinations were performed at day 14 and
21 after EAU induction using a modiﬁed Karl Storz veterinary otoendoscope
coupled with a Nikon D90 digital camera, as previously described49. Brieﬂy, fol-
lowing systemic administration of systemic anesthesia (intraperitoneal injection of
ketamine (1.4 mg/mouse) and xylazine (0.12 mg/mouse)), the pupil was dilated by
topical administration of 1% tropicamide ophthalmic solution (Alcon Inc, Fort
Worth, Texas). To avoid a subjective bias, evaluation of the fundus photographs
was conducted without knowledge of the mouse identity by a masked observer. At
least six images (2 posterior central retinal view, 4 peripheral retinal views) were
taken from each eye by positioning the endoscope and viewing from superior,
inferior, lateral, and medial ﬁelds and each individual lesion was identiﬁed, mapped
and recorded. The clinical grading system for retinal inﬂammation was as pre-
viously established31, 33.
Imaging mouse retina by SD-OCT. Spectral-domain optical coherence tomo-
graphy (SD-OCT) is a non-invasive procedure that allows visualization of internal
microstructure of various eye structures in living animals. An SD-OCT system with
1180 nm center wavelength broadband light source (Bioptigen, NC) was used for
in vivo non-contact imaging of the eyes. Before OCT imaging was performed, each
animal was anesthetized and the pupils dilated. The anesthetized mouse was
immobilized using adjustable holder that could be rotated easily allowing for
horizontal or vertical scan scanning. Each scan was performed at least twice, with
realignment each time. The dimension of the scan (in depth and transverse extent)
was adjusted until the optimal signal intensity and contrast was achieved.
Electroretinogram recordings. Before the Electroretinogram (ERG) recordings,
mice were dark-adapted overnight, and experiments were performed under dim
red illumination. Mice were anesthetized with a single intraperitoneal injection of
ketamine (1.4 mg/mouse) and xylazine (0.12 mg/mouse) and pupils were dilated
with Midrin P containing of 0.5% tropicamide and 0.5% phenylephrine hydro-
chloride (Santen Pharmaceutical Co., Osaka, Japan). ERG was recorded using an
electroretinography console (Espion E2; Diagnosys LLC, Lowell, MA, USA) that
generated and controlled the light stimulus. Dark-adapted ERG was recorded with
single-ﬂash delivered in a Ganzfeld dome with intensity of −4 to 1 log cd s/m2
delivered in 6 steps. Light-adapted ERG was obtained with a 20 cd/m2 background,
and light stimuli started at 0.3−100 cd s/m2 in 6 steps. Gonioscopic prism solution
(Alcon Labs, Fort Worth, TX, USA) was used to provide good electrical contact
and to maintain corneal moisture. A reference electrode (gold wire) was placed in
the mouth, and a ground electrode (subcutaneous stainless-steel needle) was
positioned at the base of the tail. Signals were differentially ampliﬁed and digitized
at a rate of 1 kHz. Amplitudes of the major ERG components (a- and b-wave) were
measured (Espion software; Diagnosys LLC) using automated and manual meth-
ods. Immediately after ERG recording, imaging of the fundus was performed as
previously described above.
Lymphocyte proliferation assay. B cells were stimulated with 1 µg/ml LPS (Sigma
L2654) while CD4+ T cells were cultured in plate bound anti-CD3 Ab (10 µg/ml)
and medium containing anti-CD28 Ab (1 µg/ml) Clones 145-2C11 and 37.51,
respectively; BD Biosciences). B cells or T cells were propagated in presence or
absence of p35, p35−p35, rEbi3 or rIL-35. For some co-culture experiments, LN and
spleen cells were stimulated with IRBP in medium containing p35 or rIL-35. After
72 h, cultures were pulsed with 3H-thymidine (0.5 µCi/10 µl/well) as described50.
Presented data are mean CPM± SEM of responses of 5 replicate cultures.
Detection of cytokine-expressing lymphocytes by FACS. Primary B cells iso-
lated from the spleen/LN (sorted for CD19+ or B220+) were stimulated with LPS (1
µg/ml). CD4+ T cells (>98%) from the spleen and/or LN were activated in plate-
bound anti-CD3 Abs (10 µg/ml) and soluble anti-CD28 Abs (1 µg/ml) as recom-
mended by the manufacturer (BD Pharmingen, San Diego, CA, USA) and as
previously described25. For intracellular cytokine detection, cells were re-stimulated
for 5 h with PMA (Sigma, P8139) (20 ng/ml) and ionomycin (Sigma I0634) (1 µM).
Golgi-stop was added in the last hour and intracellular cytokine staining was
performed using BD Biosciences Cytoﬁx/Cytoperm kit as recommended (BD
Pharmingen, San Diego, CA, USA). FACS analysis was performed on a Becton-
Dickinson FACSCalibur (BD Biosciences) using protein-speciﬁc monoclonal
antibodies and corresponding isotype control Abs (PharMingen, San Diego, CA,
USA) as previously described13, 25. FACS analysis was performed on samples
stained with mAbs conjugated with ﬂuorescent dyes and each experiment was
color-compensated. Dead cells were stained with dead cell exclusion dye (Fixable
Viability Dye eFluor 450; eBioscience) and live cells were subjected to side-scatter
(SSC) and forward scatter (FSC) analysis. Quadrant gates were set using isotype
controls with less than 0.2% background.
Quantitative PCR analysis. Total RNA was extracted from lymphocytes and
retinal cells using the TRIzol reagent according to the procedures recommended by
the manufacturer (Life Technologies, Gaithersburg, MD). All RNA samples were
digested with RNAse-free DNAse 1 (Life Technologies) for 30 min, puriﬁed by
phenol/chloroform extractions, and precipitated in 0.4 M LiCl. RNA (10 µg), a
commercial synthesis system (SuperScript III Reverse Transcriptase; Life Tech-
nologies), and oligo(dT) were used for ﬁrst-strand synthesis as previously descri-
bed. First-strand synthesis containing each mRNA sample but without reverse
transcriptase was performed to control for possible DNA contamination; failure to
obtain real-time PCR (RT-PCR) products with any of the PCR amplimers con-
ﬁrmed the absence of contaminating DNA. All cDNA preparations used were
suitable for PCR ampliﬁcation on the basis of efﬁcient ampliﬁcation of a β-actin
sequence. RT-PCR was performed on a fast RT-PCR system (ABI 7500) and PCR
parameters were as recommended by the manufacturer (TaqMan Universal PCR
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Kit; Applied Biosystems). Primers and probes were from Applied Biosystems: Il12a
(ABI, Mm00434169_m1), Ebi3 (ABI, Mm00469264_g), Il10 (ABI,
Mm00439616_m1), gapdh (ABI, Mm99999915_g1), actin b (Mm00469264_g1)
(Supplementary Table 1). The mRNA expression levels were normalized to the
levels of GAPDH housekeeping gene.
Western blotting analysis. Preparation of whole cell lysates and performance of
western blot analysis were as described in ref. 51. Cell extracts (20–40 µg/lane) were
fractionated on 4–12% gradient SDS-PAGE, and antibodies used were: pSTAT3
(Cell Signaling Technology, Danvers Massachusettes); IL-12p35, Ebi3, Cyclin E,
cyclin -D1, P27Kip1, pSTAT1, pSTAT3, pSTAT4, STAT4, and β-actin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) (Supplementary Table 2). Pre-immune
serum was used in parallel as controls and signals were detected with HRP-
conjugated secondary F(ab′)2 Ab (Zymed Laboratories) using the ECL-PLUS sys-
tem (Amersham, Arlington Heights, IL, USA).
Statistical analysis. Statistical analysis was performed by Student’s t-test
(two-tailed) at 95% conﬁdence level using Prism 7 software. EAU scores were
analyzed by non-parametric Mann−Whiney U-test (two-tailed). Asterisks denote
P-value (*P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001).
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles, or are
available from the authors upon request.
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